Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Immune Challenge Study
NCT06021002Active, not recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of resiquimod in allergic rhinitis (AR) and asthma (7 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Nasal CXCL10 gene expression baseline vs post-challenge at 24 hours. Started Aug 2022; status: active, not recruiting.
02
Drugs
resiquimod
03
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on NCT06021002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021002.